Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.
The synthetic triterpenoid methyl-2-cyano-3,12-dioxoolean-1,9-dien-28-oate (CDDO-Me) is in phase I clinical trials as a novel cancer therapeutic agent. We previously showed that CDDO-Me induces c-Jun NH(2)-terminal kinase (JNK)-dependent death receptor 5 (DR5) expression and augments death receptor-induced apoptosis. The current study focused on addressing how CDDO-Me induces JNK-dependent DR5 expression. Analysis of DR5 promoter regions defines that the CCAAT/enhancer binding protein homologous protein (CHOP) binding site is responsible for CDDO-Me-induced transactivation of the DR5 gene. Consistently, CDDO-Me induced DR5 expression and parallel CHOP up-regulation. Blockade of CHOP up-regulation also abrogated CDDO-Me-induced DR5 expression. These results indicate that CDDO-Me induces CHOP-dependent DR5 up-regulation. Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well. Importantly, knockdown of CHOP attenuated CDDO-Me-induced apoptosis, showing that CHOP induction is involved in CDDO-Me-induced apoptosis. Additionally, CDDO-Me increased the levels of Bip, phosphorylated eukaryotic translation initiation factor 2alpha, inositol requiring kinase 1alpha, and activating transcription factor 4, all of which are featured changes during endoplasmic reticulum (ER) stress. Furthermore, salubrinal, an inhibitor of ER stress-induced apoptosis, inhibited JNK activation and up-regulation of CHOP and DR5 by CDDO-Me and protected cells from CDDO-Me-induced apoptosis. Thus, ER stress seems to be important for CDDO-Me-induced JNK activation, CHOP and DR5 up-regulation, and apoptosis. Collectively, we conclude that CDDO-Me triggers ER stress, leading to JNK-dependent, CHOP-mediated DR5 up-regulation and apoptosis.
Zou
Wei
W
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Yue
Ping
P
Khuri
Fadlo R
FR
Sun
Shi-Yong
SY
D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D004721:Endoplasmic Reticulum / Q000187:drug effects* / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D048670:MAP Kinase Kinase 4 / Q000378:metabolism*; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000096:biosynthesis* / Q000235:genetics; D051742:Transcription Factor CHOP / Q000096:biosynthesis*; D014158:Transcription, Genetic; D015854:Up-Regulation / Q000187:drug effects
C497249:DDIT3 protein, human; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D051742:Transcription Factor CHOP; D009828:Oleanolic Acid; C445068:bardoxolone methyl; D048670:MAP Kinase Kinase 4; D005978:Glutathione
J Biol Chem. 2007 Jun 29;282(26):18800-9
17493934
J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80
15572759
Exp Cell Res. 2001 Jan 15;262(2):154-69
11139340
Exp Gerontol. 2004 May;39(5):735-44
15130668
Nature. 2000 Oct 12;407(6805):770-6
11048727
Oncogene. 2000 Mar 30;19(14):1735-43
10777207
J Cell Physiol. 1997 Nov;173(2):279-84
9365537
Cell Death Differ. 2004 Apr;11(4):381-9
14685163
Cancer Res. 2004 Oct 15;64(20):7570-8
15492284
Mol Cancer Ther. 2002 Jan;1(3):177-84
12467212
Semin Cell Dev Biol. 2007 Dec;18(6):716-31
18023214
Science. 2005 Feb 11;307(5711):935-9
15705855
Nat Cell Biol. 2001 Apr;3(4):409-16
11283615
Cancer Res. 2003 Sep 1;63(17):5551-8
14500394
Cancer Biol Ther. 2006 May;5(5):492-7
16582599
Cancer Res. 1998 Apr 15;58(8):1593-8
9563466
Oncogene. 2001 Apr 19;20(17):2178-85
11360202
Mol Cell Biol. 2005 Jul;25(13):5404-16
15964798
J Biol Chem. 2004 Oct 29;279(44):45495-502
15322075
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3139-46
18065492
Curr Biol. 1997 Sep 1;7(9):693-6
9285725
Cancer Res. 1997 Nov 1;57(21):4931-9
9354460
J Biol Chem. 2006 Nov 24;281(47):35764-9
16998237
Cancer Res. 2005 Jul 1;65(13):5662-7
15994939
Oncogene. 1999 Nov 11;18(47):6411-8
10597242
Mol Pharmacol. 2007 Nov;72(5):1269-79
17684158
Blood. 2002 Jan 1;99(1):326-35
11756188
Cancer Res. 2007 May 1;67(9):4210-8
17483332
Clin Cancer Res. 2006 Mar 15;12(6):1828-38
16551868
Bioorg Med Chem Lett. 1999 Dec 20;9(24):3429-34
10617085
J Biol Chem. 2007 Feb 9;282(6):3989-97
17158450
Mol Cancer Ther. 2004 Jan;3(1):39-45
14749474
J Immunol. 1999 Mar 1;162(5):2597-605
10072501
J Biol Chem. 2005 Oct 28;280(43):36273-82
16118208
Nat Genet. 1997 Oct;17(2):141-3
9326928
Carcinogenesis. 2006 Apr;27(4):717-28
16332727
Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29
17565364
Oncogene. 1999 Apr 8;18(14):2357-65
10327056
Cancer Res. 2008 Jul 1;68(13):5335-44
18593935
Cancer Res. 2007 Mar 15;67(6):2414-9
17363558
Nat Rev Cancer. 2007 May;7(5):357-69
17446857
EMBO Rep. 2006 Sep;7(9):880-5
16953201